TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Sept. 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held virtually October 13 – 15, 2021. Regular abstracts are now available through the ECTRIMS platform and late-breaking abstracts will be accessible on October 13, 2021. Additional presentation details, including a direct link to the currently available abstract is included below.
- Regular abstracts are now available through the ECTRIMS platform and late-breaking abstracts will be accessible on October 13, 2021.
- To attend the live event, please visit the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events .
- Following the live event, an archive file will be available for replay, for a period of 30 days after the call.
- The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries.